Misconceptions that patients are prone to in the consultation process: Misconception 1: Misconceptions about the contagiousness of hepatitis. Viral hepatitis that causes chronic liver damage is mainly hepatitis B and C, while hepatitis A and E are a cause of acute hepatitis, basically not chronic, hepatitis A and E are transmitted through the digestive tract, while hepatitis B and C are transmitted through blood, body fluids, mother-to-child vertical, traumatic medical devices, etc. Daily work or life contacts, such as working in the same office (including sharing office supplies such as computers), shaking hands Hepatitis B and C are generally not transmitted through daily work or life contacts, such as working in the same office (including sharing office supplies such as computers), shaking hands, hugging, living in the same dormitory, eating together, sharing toilets and other contacts without blood exposure. Therefore, for HBsAg(+) or slow hepatitis C patients, first of all, they should be clear about the mode of transmission of their disease, do not have an inferiority complex and isolate themselves from their family and friends, and secondly, they should educate people around them to have the correct medical knowledge and not to discriminate against slow hepatitis B and C patients. It has been proven that one of the spouses has hepatitis B or C, but the other spouse has lived with them for decades without being infected. As long as there are scientific and correct means of protection and avoiding blood exposure, you will not be infected. This is also the scientific basis for the Ministry of Health’s introduction of the hepatitis B-related indicators that are not allowed to be checked during medical examinations for entry into the workforce. Myth 2: Misconceptions about diagnosis and testing. Some chronic hepatitis B patients and even non-hepatology medical professionals, there is a common understanding that “small three yang” is good and “large three yang” is not good, which is a completely wrong idea. Whether it is “big three yang” or “small three yang”, there are chronic hepatitis B carriers and slow hepatitis B patients, if they are carriers, it means that the disease is relatively stable, basically no obvious liver function damage, can withstand normal work and study tasks; if they are chronic active or cirrhotic patients, it is necessary to carry out treatment. The so-called major and minor triplets refer to the e antigen-positive or e antigen-negative immune index of hepatitis B. Those who are positive are major triplets and those who are negative are minor triplets, which only reflect the immune marker status of hepatitis B in the body and do not represent the severity of the disease or the size of the infection. The severity of the disease depends on the indicators of liver function and liver imaging and pathology, while the infectiousness depends on the viral load in the blood. Therefore, many carriers with major triplets do not need treatment for the time being, but should be reviewed regularly, while patients with minor triplets should be analyzed on a case-by-case basis, first to determine whether the virus is positive (i.e., whether HBV-DNA is positive), whether liver function is normal, and whether liver imaging shows signs of liver fibrosis or even cirrhosis. If the liver function is abnormal, DNA-positive “small three yang” is required to actively treat, should not use their own “small three yang” and delay treatment. Myth 3: Misconceptions about hepatitis treatment. The most common misconception about treatment is the lack of understanding of the importance of antiviral therapy and the course of treatment. The reason why chronic hepatitis develops into chronic, the most critical point is that the virus can not be cleared by the body’s immune system and long-term latent in the body, repeatedly destroy liver cells and lead to chronic activity and even liver fibrosis, liver stiffness, when the virus destroys liver cells, liver cell necrosis lysis, cell plasma or mitochondria in the release of various enzymes into the blood, causing the blood enzyme levels to rise, such as glutathione transaminase, glutathione transaminase. The elevation of enzymes reflects the damage of liver cells, and enzyme-lowering treatment is a symptomatic treatment, and the reduction of transaminases to normal is not equal to the cure of chronic hepatitis. Therefore, antiviral treatment is the most important treatment of all kinds of treatment, only by suppressing or even removing the virus can we solve the phenomenon of repeated damage to liver cells, repeated hepatitis activity and repeated elevation of transaminases. However, due to the difficulty and medical limitations of antiviral therapy, there is no “cure-all” drug that can completely eliminate the virus in a relatively short period of time. At present, there are two major categories of effective anti-hepatitis B virus drugs: interferon and nucleoside (acid) class, and the treatment time frame of these two types of drugs is relatively long. Interferon therapy is six months to two years, and nucleoside (acid) therapy is three to five years or even longer. Long-term drug therapy is required for patients with decompensated cirrhosis. Therefore, for the treatment of chronic hepatitis B, we should establish the basic concept of antiviral treatment as long as there are indications, and also establish the concept of long-term treatment and lasting battle with the virus, never believe in the “charlatan doctors” and some false advertising so-called “how long does it take to convert the Australian anti The “How long does it take to turn negative”, “turn negative rate of 100 percent” and so on propaganda. There may be “special cases” and “cases” of HBsAg conversion in your neighborhood, but most likely they are acute hepatitis B. Acute hepatitis B is a self-limiting disease, the natural negative rate of more than 90%, while the slow hepatitis B surface antigen is difficult to negative, the natural negative rate of 1 to 3%, is the need for long-term treatment. Myth 4: Insufficient awareness of regular review of chronic hepatitis B carriers or patients. In clinical work, many hepatologists often see patients first diagnosed with cirrhosis or liver disease, which has developed to an advanced stage and is difficult to treat, and this phenomenon is more common. By following up the medical history, we find that these patients know that they are HBsAg (+) carriers, but they do not review regularly and do not seek medical treatment, often using “busy work” and “no abnormal feeling” as the reason for not checking regularly, and once It is a great pity that once you “feel” the disease is at an advanced stage. How to avoid this kind of tragedy, only to strengthen the patient’s self-management, regular review, always understand the changes in their own condition is the best means, never “feel, have discomfort” as the reason to visit the doctor. Chronic viral hepatitis disease progression is mostly caused by “no feeling”, the virus latent in the liver cells, in the accumulation of months and years quietly cause liver cell damage, fibrosis and even cirrhosis. Therefore, the patient and the specialist should closely monitor this process and use antiviral drugs in a timely manner to stop the process of quantitative to qualitative changes caused by the virus, while for patients who are already on antiviral therapy, it is more important to review regularly and establish a good doctor-patient relationship with the doctor. Through regular review of liver function and virological indicators, observe the efficacy of antiviral therapy, timely detection of adverse reactions to antiviral therapy, such as the side effects of interferon therapy and the occurrence of resistance to nucleoside oral drugs, timely adjustment and change of treatment plan, to fundamentally achieve the purpose of stopping the progress of the disease, improve the quality of life and prolong life. Myth #5: Give up your fertility requirements because you are a HBsAg (+) carrier. Some chronic hepatitis B virus carriers, for fear of infecting their children, give up their fertility requirements, and even some young people refuse to talk about a date, refuse to get married, and this phenomenon is also relatively common. In recent years, with the popularization of the vaccine, the rate of HBsAg (+) carriage in newborns and children has dropped significantly, and the success rate of mother-to-child interruption is above 90%. Therefore, HBsAg (+) carriers can give birth to healthy babies like normal people as long as they have the conditions to do so, but always remember to consult with obstetrics and gynecology and liver disease specialists to carry out mother-to-child blocking strategies.